The Hepcidin pipeline drugs market research report outlays comprehensive information on the Hepcidin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Hepcidin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, and Hematological Disorders which include the indications Polycythemia Vera, Acute Inflammation, and Anemia. It also reviews key players involved in Hepcidin targeted therapeutics development with respective active and dormant or discontinued products.
The Hepcidin pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Preclinical stages are 1, and 4 respectively.
Hepcidin overview
Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.
For a complete picture of Hepcidin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
